06/16/2026
"How do we know whether our COA is relevant for our study?” is a common question that we get from our sponsors.
By the time a COA is implemented in a trial, sponsors may still face critical questions. Will patients understand the instrument as intended? Are the response options and recall period appropriate? Does the measure capture concepts that are meaningful in real-world settings? And will the resulting data be interpretable and credible to regulators?
Prospective mixed-methods studies are designed to answer these questions before they become risks.
By integrating qualitative and quantitative approaches, these studies allow sponsors to evaluate how a COA performs in practice. Qualitative interviews can assess relevance, clarity, and alignment with lived experience, while quantitative data can evaluate feasibility, completion rates, score distribution, reliability, validity, and early responsiveness. Together, these insights help determine whether an instrument is truly fit for purpose.
This is also where regulatory expectations have become more specific. U.S. Food and Drug Administration's PFDD Guidance 3 emphasizes that fit-for-purpose COAs should measure what matters to patients and be supported by evidence on item relevance, response options, and recall period. PFDD Guidance 4 further emphasizes that COA-based endpoints and interpretation of change should be well-supported by evidence, including evidence relevant to meaningful within-patient change.
At Clinical Outcomes Solutions, our Qualitative and Prospective Studies teams design studies that simulate real-world COA use, assess patient burden, evaluate administration modes, and generate early evidence to support the measure's interpretability and its meaningfulness to patients.
In a landscape where endpoint strategy can shape trial success, evaluating COA feasibility and relevance early is not just helpful; it's essential.
